ABSTRACT: Muscle injury is one of the most common orthopedic and sports disorders. For severe cases, surgical repair may be indicated; however, other than immobilization and the administration of anti-inflammatory drugs there is currently no effective conservative treatment for this condition. Satellite cells (SCs) are muscle-specific stem cells and are indispensable for muscle regeneration after muscle injury. SCs are activated upon muscle injury to proliferate and differentiate into myoblasts, which subsequently fuse into myofibers and regenerate the damaged muscle. We have previously shown that ADAM10, a membrane-anchored proteolytic enzyme, is essential for the maintenance of SC quiescence by activating the Notch signaling pathway in SCs. Because suppression of ADAM10 activity in SCs can activate SC differentiation, we asked whether inactivation of ADAM10 in SCs after muscle injury could enhance muscle regeneration. Using Adam10 conditional knockout mice, in which ADAM10 activity can specifically be suppressed in SCs, we found that partial inactivation of ADAM10 accelerates muscle regeneration after muscle injury. Nearly identical results were obtained by the administration of GI254023X, a selective ADAM10 inhibitor. The findings of the present study thus indicate that transient enhancement of SC differentiation after muscle injury expedites muscle regeneration and that ADAM10 can be a potential molecular target in treating muscle injuries. ß
Satellite cells (SCs) are muscle-specific stem cells that are indispensable for muscle regeneration. 1, 2 Although SCs are in a quiescent state under normal conditions, they reenter the cell cycle upon muscle injury and differentiate to form new muscle fibers. After completing the regenerative phase, a fraction of SCs return to the quiescent state. [3] [4] [5] SCs are known to decrease in number and to lose their regenerative potential with aging, leading to age-related muscle weakness and a decrease in muscle regeneration capacity. 3, [6] [7] [8] Of note, several studies have shown that muscle regenerating capacity could be rescued by rejuvenating the SC population in aged mice. [9] [10] [11] However, there are currently no valid therapeutic interventions for patients with muscle injury. Given that muscle injury (such as muscle strain and muscle tear) is one of the most common sports injuries, there is a great demand to establish a novel treatment modality.
The Notch signaling pathway is a highly conserved intracellular pathway that is involved in cell fate determination, differentiation, thereby maintaining homeostasis in various tissues. In the context of muscle homeostasis, previous studies have shown that the Notch signaling pathway is constitutively activated in SCs and plays an indispensable role in maintaining SC quiescence by preventing premature differentiation. [12] [13] [14] [15] In accordance, the complete abrogation of Notch signaling in SCs results in a loss of the SC pool and impaired muscle regeneration after muscle injury. 12, 14, 15 In mammals, there are four Notch receptors (Notch1-4) and five Notch ligands (JAG1, JAG2, DLL1, DLL3, and DLL4), which are all membrane-bound proteins. Upon ligand binding, Notch protein undergoes sequential proteolytic cleavage (S2 and S3 cleavage) by two different proteolytic enzymes and releases its intracellular domain into the cytosol. Subsequently, the Notch intracellular domain translocates into the nucleus and functions as a transcriptional activator. The gamma secretase complex is responsible for the S3 cleavage, whereas we and others have shown that ADAM10 is the major enzyme involved in the S2 cleavage in mammals. [16] [17] [18] [19] [20] ADAM10 is a membrane-anchored proteolytic enzyme that is closely related to ADAM17 (aka, TNFa-converting enzyme [TACE]), which is essential for the processing of pro-TNFa and the membrane-bound proform of the epidermal growth factor receptor ligands. [21] [22] [23] [24] [25] To elucidate the role of ADAM10 in SCs, we previously generated a mutant mouse line in which ADAM10 is conditionally abrogated in SCs (henceforth referred to as Adam10 Pax7 mice). 16, 18 Deletion of the Adam10 allele in SCs during postnatal growth did not result in any gross defects in skeletal muscles; however, the mutant mice demonstrated severe defects in muscle regeneration after muscle injury. 18 We found that SCs lacking ADAM10 are incapable of maintaining the quiescent state and differentiate into myoblasts, leading to the depletion of the SC pool. Most importantly, further analysis revealed that suppression of ADAM10 activity induces myogenic differentiation by inactivating the Notch signaling in SCs.
These data show that ADAM10 is a key molecule in maintaining the Notch-dependent SC quiescence and indicate that the differentiation of SCs can be manipulated by artificially regulating ADAM10 activity.
In the present study, we investigated whether the partial abrogation of ADAM10 activity could enhance muscle regeneration after muscle injury by inducing SC differentiation. We used Adam10 Pax7 mice and GI254023X, a selective ADAM10 inhibitor, and found that the partial loss of ADAM10 activity expedites muscle regeneration after cardiotoxin-induced muscle injury. These results suggest that muscle regeneration can be accelerated by enhancing SC differentiation and that the ADAM10-Notch signaling axis serves as a potential molecular target in treating muscle injuries in humans.
MATERIALS AND METHODS

Mice
Adam10 Pax7 mice were generated by crossing Adam10 flox/flox mice and Pax7 TM2.1(cre/ERT2)Fan /J transgenic mice as previously described. 16, 18 Deletion of the Adam10 allele was achieved by serial intraperitoneal injections of a tamoxifen (75 mg/kg, Toronto Research Chemicals, Toronto, Canada)/corn oil solution as outlined in Figure 1A . Please note that in the present study, tamoxifen was used at 2-5 days post-injury (DPI), and therefore, the Adam10 floxed allele or the SC population were not fully abrogated during muscle regeneration. On the other hand, in our previous study, 18 we treated 3-week-old mice with tamoxifen consecutively for 5 days and once a week afterward until they reached 9-week-old so as to fully abrogate ADAM10 and deplete SCs. Adam10 flox/flox mice do not exhibit any notable defects and were used as control (Ctrl) animals. C57BL/6J male mice were purchased from CLEA Japan (Tokyo, Japan), and 8-9-week-old mice were used in the present study. All mice were maintained under specific pathogen-free conditions and were given food and water ad libitum. All animal experiments were approved by the Institutional Animal Care and Use Committee of the Keio University School of Medicine (approval number: 11022).
Reagents and Antibodies
Anti-PAX7 antibody (sc-81648, 1:50) was purchased from Santa Cruz (Dallas, TX). Anti-Laminin 2 antibody (L0663, Pax7 mice at 5, 7, and 14 DPI. n ¼ 6 specimens (three mice)/group (7 and 14 DPI), or n ¼ 4 specimens (two mice)/group (5 DPI). ns, not significant. ÃÃ , p < 0.005.
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1:500) and the selective ADAM10 inhibitor (GI254023X) 26 were purchased from Sigma-Aldrich (St. Louis, MO),
Muscle Injury Model
Muscle injury was induced by intramuscular injection of cardiotoxin (CTX) to the tibialis anterior (TA) muscle as previously described. 18 Animals were anesthetized by intraperitoneal injection of a mixture of sterilized water, medetomidine (30 mg/ml), midazolam (400 mg/ml), and butorphanol (500 mg/ml) at a volume of 0.1 ml per 10 g body weight prior to CTX injection and monitored until full recovery. GI254023X dissolved in dimethyl sulfoxide (DMSO; 20 mM, 100 ml/mouse) was intraperitoneally injected following the protocol outlined in Figure 3B . Both lower limbs were used for the analyses. Based on other studies with similar experiments, [27] [28] [29] we used six specimens (three mice) for CSA analysis (except for the CSA analysis at 5 DPI ( Fig. 1B and C ; four specimens).
Histology and Evaluation of the Cross-Sectional Area
Fresh frozen sections of the TA muscles were used for histology and for the analysis of cross-sectional area (CSA) of muscle fibers. Sections stained with hematoxylin and eosin (HE) were used for CSA analysis. The whole damaged area in each section was evaluated. The measurement of CSA was performed by a single examiner (S.M.). For immunofluorescence staining, sections were blocked with the blocking solution (PBS containing 2% BSA and 5% goat serum). A Mouse on Mouse Immunodetection Kit (Vector Laboratories, Burlingame, CA) was used as instructed by the manufacturer. An Olympus FSX100 fluorescence microscope (Olympus, Tokyo, Japan) and Olympus FSX-BSW software were used for image collection. Images were processed using Adobe Photoshop CS6 (Adobe Systems, San Jose, CA) and analyzed using ImageJ software (National Institutes of Health, Bethesda, MD).
Statistical Analysis
Student's t test was used to determine statistical significance between two groups. p < 0.05 was considered statistically significant. GraphPad Prism software (Version 6.05; La Jolla, CA) was used for statistical calculations. The data are presented as the mean AE SD.
RESULTS
Partial Abrogation of Adam10 in SCs After Muscle Injury Accelerates Muscle Regeneration Muscle injury was induced by an intramuscular injection of cardiotoxin to the TA muscle. Partial deletion of the Adam10 allele in SCs was induced in Adam10
Pax7 mice by intraperitoneal injection of tamoxifen from 2 to 5 DPI as outlined in Figure 1A . Control mice were similarly treated with tamoxifen. Muscle specimens were collected on 5, 7, and 14 DPI. Sections of both Ctrl and Adam10
Pax7 mice at 5 DPI similarly showed numerous inflammatory cells and immature regenerating muscle fibers with expanded interstitial space (Fig. 1B, upper  panels) . There was no apparent difference in the size of regenerating muscle fibers at this time point (Fig. 1C,  upper panels) . However, the regenerating muscle fibers were significantly larger in Adam10
Pax7 mice than in Ctrl mice at 7 DPI, indicating that muscle regeneration was accelerated in Adam10 Pax7 mice (Fig. 1B and C , middle panels). By 14 DPI, the damaged muscles were fully recovered in both Ctrl and Adam10 Pax7 mice, and there was no significant difference in the size of the muscle fibers between Ctrl and Adam10 Pax7 mice (Fig. 1C and D, lower panels) . Taken together, these observations suggest that conditional abrogation of Adam10 after muscle injury expedites the muscle regeneration processes but has little effect on the size of muscle fibers after their recovery.
Pharmacological Inhibition of ADAM10 Activity Facilitates Muscle Regeneration
We next examined whether the administration of an ADAM10 inhibitor (GI254023X) exhibits a similar effect on muscle regeneration as observed in Adam10 Pax7 mice after muscle injury. As shown in Figure 2A , GI254023X or DMSO was administered from 2 to 5 DPI. The muscle specimens were collected for analysis on 7 and 14 DPI. Consistent with the experiments using the conditional knockout mice (Fig. 1B and C) , muscle regeneration was nearly completed by 14 DPI in both DMSO-and GI254023X-treated mice (Fig. 2B and C, lower panels). Of note, we found that GI 254023X-treated mice had significantly larger muscle fibers than DMSO-treated control animals at 7 DPI (Fig. 2B and C, upper panels) . These results show that pharmacological inhibition of ADAM10 by GI254023X is sufficient to enhance muscle regeneration, at least under the present experimental conditions. Administration of GI254023X Does Not Result in the Depletion of the SC Pool As the full abrogation of Adam10 in SCs during postnatal growth leads to the depletion of the SC pool in vivo, 18 we also investigated whether the administration of GI254023X after muscle injury would affect the SC population. Following the induction of muscle injury, mice were treated either with DMSO or GI254023X from 2 to 5 DPI. Muscle tissues were collected on 28 and 56 DPI for analysis. The muscle tissues were sectioned and stained for PAX7, a specific marker for satellite cells (Fig. 3A) . In DMSO-treated control mice, the number of cells that were positive for PAX7 was elevated at 28 DPI and returned to basal level by 56 DPI (Fig. 3B) . A similar trend was observed in the mice treated with GI254023X; however, the numbers of PAX7-positive cells were lower in GI254023X-treated mice compared with DMSOtreated animals at 28 DPI. Most importantly, there was no difference in the number of PAX7-positive cells between DMSO-and GI254023X-treated mice at 56 DPI, indicating that the administration of GI254023X did not fully abrogated ADAM10 activity in SCs and had little impact on the SC population after the recovery from muscle injury under the present experimental conditions.
SUPPRESSION OF ADAM10 ENHANCES MUSCLE REGENERATION
We next asked whether the muscle regeneration capacity was maintained after GI254023X treatment. As outlined in Figure 3C , we treated the injured wildtype mice with DMSO or GI254023X from 2 to 5 DPI and induced a secondary muscle injury on 28 DPI (the damaged muscle tissues were fully recovered in both DMSO-and GI254023X-treated mice by this time point (data not shown)). Mice were sacrificed on 35 DPI (7 days after the secondary injury) for histological analysis. As a negative control, we prepared Adam10-Pax7 mice in which SCs were fully depleted by serial injections of tamoxifen, as previously described.
18
Adam10
Pax7 mice were similarly treated with cardiotoxin and analyzed on 7 DPI. As shown in Figure 3D and E, we found that the degree of muscle regeneration was comparable between DMSO-and GI254023X-treated mice, and there were no apparent fibrous or adipose tissues. By contrast, as we have previously described, there were marked adipose and fibrous tissues in the sections of Adam10 Pax7 mice, which reflected the impaired muscle regeneration in these mice. Taken together, these observations show that SCs in GI254023X-treated mice were fully functional even after the secondary muscle injury under the present experimental conditions.
DISCUSSION
We have previously shown that ADAM10 expressed in SCs functions as a gatekeeper of SC differentiation and that the suppression of ADAM10 activity prompts SC differentiation. 18 This finding led to the hypothesis that SC differentiation could be artificially manipulated by regulating ADAM10 activity in vivo. Here, we showed that partial abrogation of the Adam10 gene using Adam10
Pax7 mice and pharmacological inhibition of ADAM10 using GI254023X can both accelerate muscle regeneration after muscle injury in mice. The present study therefore suggests that the induction of SC differentiation can improve recovery from muscle injury and that ADAM10 may serve as a potential molecular target in enhancing SC differentiation.
Muscle injury triggers a cascade of events, which consists of three major phases: the degeneration/ inflammation phase, the regeneration phase, and the remodeling phase. 30 The degeneration/inflammation phase is characterized by the necrosis of muscle tissues, the infiltration of immune cells, and the formation of edema and hematoma. The regeneration phase refers to the removal of necrotic tissues by phagocytosis and the regeneration of myofibers through the proliferation and differentiation of SCs. Finally, in the remodeling phase, regenerated muscle fibers mature and fully recover their functions. Past studies have shown that the regeneration phase, especially the proliferation of myoblasts, can be facilitated by the topical injection of growth factors, including HGF, FGF, PDGF, IGF-I, and G-CSF. [30] [31] [32] [33] [34] In line with this idea, the potential application of platelet-rich plasma, which contains various growth factors with pro-myogenic activity, for muscle injuries has been explored. 35, 36 Furthermore, VEGF enhances muscle regeneration by promoting angiogenesis and thereby potentially improving the delivery of nutrients and oxygen to the injured site. In contrast to these growth factors, the suppression of ADAM10 activity has little effect on the proliferation of SCs (unpublished observation); however, the suppression of ADAM10 activity attenuates the Notch signaling pathway and promotes the differentiation of SCs into myoblasts. 18 In this regard, our data may provide a novel view that muscle regeneration can be accelerated not only by promoting the proliferation of myoblasts but also by inducing the differentiation of SCs (and thereby increasing the number of myoblasts at the injury site). Furthermore, considering the differences in the mode of action, a combined administration of growth factors and an ADAM10 inhibitor could have a synergistic effect on enhancing myogenesis after muscle injury. However, because the Notch signaling pathway is essential for the maintenance of the quiescent state of SCs [12] [13] [14] [15] and complete abrogation of ADAM10 activity in SCs can result in the depletion of the SC pool, 18 the dosage and administration of an ADAM10 inhibitor in vivo needs to be further optimized. Nevertheless, treatment with GI254023X did not result in the depletion of the SC pool in the present study, as evidenced by the comparable number of PAX7-positive cells in GI254023X-treated mice to DMSO-treated control mice after muscle regeneration (Fig. 3A) and the retention of muscle regenerative capacity after the consecutive muscle injuries in these mice ( Fig. 3B and C) . These observations suggest that the potential adverse effects of GI254023X on the SC pool can be compensated by the remaining undifferentiated SCs in vivo. In addition, it is also worth mentioning that while a partial suppression of ADAM10 activity expedites muscle regeneration, it does not lead to an increase in the size of the mature muscle fibers after the completion of regeneration (Fig. 2C) .
There are several limitations to this study. Most critically, as ADAM10 is ubiquitously expressed in various cell types, 24, 25 we cannot exclude the possibility that the accelerated muscle regeneration observed in GI254023X-treated mice was, at least in part, derived from the exogenous effects from cells other than SCs. Nevertheless, given that the accelerated muscle regeneration was observed to a similar degree in Adam10
Pax7 mice (in which ADAM10 is suppressed specifically in SCs), any potential contribution of other cell types is likely to be negligible. In a similar vein, as ADAM10 has several target molecules, the potential Pax7 mice, in which the Adam10 allele in SCs were fully abrogated as previously described. 18 Bar, 100 mm. (E) Frequency distribution (left panel) and the average (right panel) of the cross-sectional area (CSA) of the regenerating muscle fibers of the TA muscles collected from DMSO-and GI254023X-treated mice at 35 DPI. n ¼ 6 specimens (three mice)/group. ns, not significant.
SUPPRESSION OF ADAM10 ENHANCES MUSCLE REGENERATION
involvement of other ADAM10 substrates that are not related to the Notch signaling pathway cannot be excluded. Next, because cardiotoxin injection induces a rapid and short-lasting muscle degeneration and inflammation, it is not evident whether the enhancement of SC differentiation would similarly be beneficial for the treatment of disorders with chronic muscle degeneration. In addition, although it is clear from our results that the partial inhibition of ADAM10 increases the size of muscle fibers in the regeneration phase, there were no apparent differences in muscle volume or in histology between Ctrl and GI254023X-treated mice (data not shown). Therefore, it remains to be addressed if the increase in CSA of muscle fibers at this phase actually reflects accelerated muscle regeneration and improved muscle quality. Lastly, because the loss of ADAM10 activity in SCs leads to myogenic differentiation of SCs, it is practically infeasible to examine the degree of ADAM10 inactivation in SCs induced in the regenerating muscles in the present models. Due to this technical difficulty, we were not able to determine the expression or activity level of ADAM10 in SCs that is required to achieve the desired effect (accelerated muscle regeneration after muscle injury) observed in the present study. Further studies are necessary to address these issues and understand what target(s) and what degree of ADAM10 inactivation will be the best to enhance muscle regeneration and function after injury.
In conclusion, our data show that partial inhibition of ADAM10 after muscle injury accelerates muscle regeneration without affecting the size of the SC pool and suggest that muscle regeneration can be improved by manipulating SC differentiation. Therefore, the present study may provide a novel view of the treatment modality of muscle injuries for which no effective treatment currently exists.
AUTHORS' CONTRIBUTION
SM performed most of the experiments, designed the study, and analyzed the data. MY and MS assisted with the experiments. KC and MN supervised the project. KH designed the experiments and wrote the paper. All authors have read and approved the final submitted manuscript.
